Can RNAi-mediated hsp90α knockdown in combination with 17-AAG be a therapy for glioma? (2013)
Tat48–60 / sihsp90α complex + 17-AAG
Sequence: H-GRKKRRQRRRPPQ-NH2
| Experiment Id | EXP002451 |
|---|---|
| Paper | Can RNAi-mediated hsp90α knockdown in combination with 17-AAG be a therapy for glioma? |
| Peptide | Tat48–60 / sihsp90α complex + 17-AAG |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | Tat CPP 15–50-fold molar excess to siRNA |
| Rna Concentration | 200 nM siRNA; 0.225 µM 17-AAG |
| Mixing Ratio | siRNA:peptide molar ratios 1:15–1:50 |
| Formulation Format | non-covalent CPP/siRNA complex plus 17-AAG |
| Formulation Components | Tat48–60 CPP + sihsp90α + 17-AAG |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | U87-MG glioblastoma cells; SVGp12 non-tumorigenic cells used as specificity/toxicity comparison |
| Animal Model | |
| Administration Route | cell culture incubation; 17-AAG added after 4 h |
| Output Type | hsp90α knockdown; Hsp90α protein reduction; Akt activity; viability; cell-cycle arrest |
| Output Value | Combination: up to 95% hsp90α mRNA knockdown, 98% Hsp90α protein reduction, 84% Akt activity attenuation, and 88% U87-MG growth inhibition |
| Output Units | |
| Output Notes | Functional in vitro RNAi effect was demonstrated and enhanced by 17-AAG; because this row is in vitro, delivery_success_class remains 0 |
| Toxicity Notes | Combination caused minimal cytotoxicity in non-tumorigenic SVGp12 cells (≤~7% growth inhibition); CPP alone showed minimal long-term toxicity |
| Curation Notes |